But EyePoint appears to have reversed its fortunes thanks to positive new interim data on its lead asset in diabetic macular edema (DME). In the midstage VERONA trial, Duravyu delivered “early ...

Liberals are calling on Ontario’s auditor general to investigate a critical shortage in medical supplies that has left vulnerable home-care patients — some in their final days — without ...

DME is a disease driven by anti-vascular endothelial growth factor (VEGF) and inflammatory mechanisms. Historically, 50% of DME patients do not respond completely to anti-VEGF therapies due to other ...